|
|
|
|
|
|
|
Mon T W Th F |
|
29 June, 2026 |
|
|
sponsored by
|
|
|
|
Recruit NYC’s Top Biotech Talent at Biotech XYZ's Inaugural Career Fair
|
| Biotech XYZ's Inaugural Career Fair offers a unique opportunity to connect with a targeted biotech talent pool from across NYC's life sciences community. Recruit for internship and full-time roles, access candidate resume books, increase brand visibility, and engage directly with future biotech leaders through employer booths and industry speaking opportunities. |
|
|
|
|
|
|
|
|
|
|
|
|
|
We're looking to celebrate 20 women who are changing the biopharma industry as we know it. You don't have to be in R&D to be nominated. Last year, we spoke with a leader at the forefront of Sanofi’s business development efforts, a venture partner who helps turn promising science into new startups, and an executive focused on patient engagement. Help us find our next group of honorees by submitting a nomination here before July 10. |
|
|
|
Nicole DeFeudis |
Senior Reporter, Endpoints News
@Nicole_DeFeudis
|
|
|
|
|
|
|
by Kyle LaHucik
|
John Reed has overseen the pipelines of three of the largest drugmakers since leaving Southern California's Sanford Burnham medical research institute 13 years ago, giving... | |
|
|
|
|
|
|
by Anna Brown
|
More than 200 biopharma investors and firms have signed an open letter calling for European governments to improve Europe’s life sciences sector. The Friday letter... | |
|
|
|
|
|
|
by Elizabeth Cairns
|
On the face of it, nearly $1 billion seems like a lot to spend on a biotech like Theravance. The company was clearly running out... | |
|
|
|
|
|
|
|
|
by Drew Armstrong
|
About a decade ago, when I had just started covering pharma, one of the biggest stories was tax inversions. For those who don’t remember, tax... | |
|
|
|
|
|
|
by Anna Brown
|
The FDA has issued Sobi, also known as Swedish Orphan Biovitrum, a complete response letter for its combination gout treatment over production concerns and issues... | |
|
|
|
|
|
|
by Ayisha Sharma
|
Ipsen is earmarking up to $1.75 billion to take Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016... | |
|
|
|
|
|
